Clinical Trial Update: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II study of Abemaciclib plus Elacestrant for brain metastases stemming from HR+/HER2- breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Orserdu (Elacestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Criterium, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED